{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T22:58:41Z","timestamp":1765666721753},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,10,26]],"date-time":"2006-10-26T00:00:00Z","timestamp":1161820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2006,10,31]]},"DOI":"10.1007\/s11096-006-9021-y","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T07:58:56Z","timestamp":1161763136000},"page":"207-214","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacoeconomic comparison of Helicobacter pylori eradication regimens"],"prefix":"10.1007","volume":"28","author":[{"given":"Mesut","family":"Sancar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fikret Vehbi","family":"Izzettin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sule","family":"Apikoglu-Rabus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Besisik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"Tozun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Dulger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,10,26]]},"reference":[{"key":"9021_CR1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(84)91816-6","volume":"1","author":"BJ Marshall","year":"1984","unstructured":"Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311\u20135","journal-title":"Lancet"},{"key":"9021_CR2","first-page":"1565","volume":"156","author":"SO Veldhuyzen","year":"1997","unstructured":"Veldhuyzen SO, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Can Med Assoc J 1997;156:1565\u201372","journal-title":"Can Med Assoc J"},{"key":"9021_CR3","first-page":"246","volume":"91","author":"G Treiber","year":"1996","unstructured":"Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996;91:246\u201357","journal-title":"Am J Gastroenterol"},{"key":"9021_CR4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.5694\/j.1326-5377.2005.tb00052.x","volume":"183","author":"MB Weyden Van Der","year":"2005","unstructured":"Van Der Weyden MB, Armstrong RM, Gregory AT. The 2005 Nobel Prize in physiology or medicine. The Helicobacter story illustrates some of the human hallmarks of revolutionary research. Med J Aust 2005;183:612\u20134","journal-title":"Med J Aust"},{"key":"9021_CR5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1053\/gast.1996.v110.pm8608904","volume":"110","author":"CC McGowan","year":"1996","unstructured":"McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996;110:926\u201338","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"9021_CR6","first-page":"S15","volume":"113","author":"MF Go","year":"1997","unstructured":"Go MF. What are the host factors that place an individual at risk for Helicobacter pylori associated disease? Gastroenterology 1997;113(Suppl.):S15\u2013S20","journal-title":"Gastroenterology"},{"key":"9021_CR7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(95)90113-2","volume":"345","author":"E Bayerdorffer","year":"1995","unstructured":"Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori. MALT lymphoma study group. Lancet 1995;345:1591\u20134","journal-title":"Lancet"},{"issue":"Suppl.1","key":"9021_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2036.11.s1.6.x","volume":"11","author":"AM Fendrick","year":"1997","unstructured":"Fendrick AM. Outcomes research in Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11(Suppl. 1):95\u2013101","journal-title":"Aliment Pharmacol Ther"},{"key":"9021_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0889-8553(05)70151-5","volume":"29","author":"AM Fendrick","year":"2000","unstructured":"Fendrick AM. The role of economic evaluation in the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Clin N Am 2000;29:837\u201351","journal-title":"Gastroenterol Clin N Am"},{"key":"9021_CR10","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/jama.1995.03530130070032","volume":"274","author":"BJ Marshall","year":"1995","unstructured":"Marshall BJ. Helicobacter pylori: the etiologic agent for peptic ulcer. JAMA 1995;274:1064\u20136","journal-title":"JAMA"},{"issue":"Suppl 2","key":"9021_CR11","first-page":"59","volume":"9","author":"EJ Kuipers","year":"1995","unstructured":"Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl. 2):59\u201369","journal-title":"Aliment Pharmacol Ther"},{"key":"9021_CR12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2005.03.004","volume":"128","author":"AC Ford","year":"2005","unstructured":"Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, McColl KE, Myres P, Delaney BC. Helicobacter pylori \u201ctest and treat\u201d or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838\u201344","journal-title":"Gastroenterology"},{"key":"9021_CR13","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","volume":"99","author":"AC Ford","year":"2004","unstructured":"Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833\u201355","journal-title":"Am J Gastroenterol"},{"key":"9021_CR14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00019053-199916030-00006","volume":"16","author":"GR Tennvall","year":"1999","unstructured":"Tennvall GR, Norinder A, Ohlin B. Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. Pharmacoeconomics 1999;16:297\u2013306","journal-title":"Pharmacoeconomics"},{"key":"9021_CR15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1046\/j.1440-1746.1999.01987.x","volume":"14","author":"SY Chen","year":"1999","unstructured":"Chen SY, Wang JY, Chen J, Zhang XD, Zhang SS. Assessment of decisions in the treatment of Helicobacter pylori related duodenal ulcer: a cost-effectiveness study. J Gastroenterol Hepatol 1999;14:977\u201383","journal-title":"J Gastroenterol Hepatol"},{"issue":"SupplB","key":"9021_CR16","doi-asserted-by":"crossref","first-page":"30B","DOI":"10.1155\/2003\/903494","volume":"17","author":"N Vakil","year":"2003","unstructured":"Vakil N. Are the geographical and regional differences in Helicobacter pylori eradication? Can J Gastroenterol 2003;17(Suppl. B):30B\u201332B","journal-title":"Can J Gastroenterol"},{"key":"9021_CR17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1472-8206.2005.00340.x","volume":"19","author":"RM McLoughin","year":"2005","unstructured":"McLoughin RM, O\u2019Morain CA, O\u2019Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005;19:421\u20137","journal-title":"Fundam Clin Pharmacol"},{"key":"9021_CR18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/archinte.1995.00430180054007","volume":"155","author":"B O\u2019Brien","year":"1995","unstructured":"O\u2019Brien B, Goeree R, Mohammed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995;155:1958\u201364","journal-title":"Arch Intern Med"},{"key":"9021_CR19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/bmj.316.7145.1648","volume":"316","author":"AE Duggan","year":"1998","unstructured":"Duggan AE, Tolley K, Hawkey CJ, Logan RFA. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. BMJ 1998;316:1648\u201354","journal-title":"BMJ"},{"key":"9021_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1523-5378.2005.00288.x","volume":"10","author":"D Marko","year":"2005","unstructured":"Marko D, Calvet X, Ducons J, Gnardiola J, Tito L, Bory F. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter 2005;10:22\u201332","journal-title":"Helicobacter"},{"key":"9021_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archinte.1997.00440220091012","volume":"157","author":"JL Taylor","year":"1997","unstructured":"Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87\u201397","journal-title":"Arch Intern Med"},{"key":"9021_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0924-8579(00)00133-3","volume":"14","author":"LP Andersen","year":"2000","unstructured":"Andersen LP, Colding H, Kristiansen JE. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. Int J Antimicrob Agents 2000;14:231\u20134","journal-title":"Int J Antimicrob Agents"},{"key":"9021_CR23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1155\/2000\/709640","volume":"14","author":"N Chiba","year":"2000","unstructured":"Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 2000;14:885\u20139","journal-title":"Can J Gastroenterol"},{"key":"9021_CR24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM199510123331508","volume":"333","author":"JH Walsh","year":"1995","unstructured":"Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. NEJM 1995;333:984\u201391","journal-title":"NEJM"},{"key":"9021_CR25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1572-0241.1999.00942.x","volume":"94","author":"NN Kung","year":"1999","unstructured":"Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, et al. One week ranitidine bismuth citrate versus colloidal bismuth subcitrate based anti-helicobacter triple therapy. Am J Gastroenterol 1999;94:721\u20134","journal-title":"Am J Gastroenterol"},{"key":"9021_CR26","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(98)70101-5","volume":"115","author":"F Megraud","year":"1998","unstructured":"Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278\u201382","journal-title":"Gastroenterology"},{"key":"9021_CR27","first-page":"25","volume":"11","author":"B Kantarceken","year":"2000","unstructured":"Kantarceken B, Yildirim B, Karincaoglu M, Aladag M, Hilmioglu F. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000;11:25\u20139","journal-title":"Turk J Gastroenterol"},{"key":"9021_CR28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2036.1997.140316000.x","volume":"11","author":"S Miehlke","year":"1997","unstructured":"Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323\u20139","journal-title":"Aliment Pharmacol Ther"},{"key":"9021_CR29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1523-5378.1999.09041.x","volume":"4","author":"A Vcev","year":"1999","unstructured":"Vcev A, Stimac D, Vceva A, Takac B, Pezerovic D, Ivandic A. High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. Helicobacter 1999;4:54\u20137","journal-title":"Helicobacter"},{"key":"9021_CR30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1046\/j.1365-2036.2001.01031.x","volume":"15","author":"X Calvet","year":"2001","unstructured":"Calvet X, Gene E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for Helicobacter pylori? Aliment Pharmacol Ther 2001;15:1067\u201376","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl.215","key":"9021_CR31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/00365529609094543","volume":"31","author":"B J\u00f6nsson","year":"1996","unstructured":"J\u00f6nsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996;31(Suppl. 215):90\u20135","journal-title":"Scand J Gastroenterol"},{"key":"9021_CR32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1523-5378.2005.00333.x","volume":"10","author":"P Bytzer","year":"2005","unstructured":"Bytzer P, O\u2019Morain C. Treatment of Helicobacter pylori. Helicobacter 2005;10:40\u201346","journal-title":"Helicobacter"},{"key":"9021_CR33","unstructured":"Clifton S, Galt K. Treatment of Helicobacter pylori infection. Immanuel Medical Center Pharmacy Memo 1997"},{"key":"9021_CR34","first-page":"27","volume":"10","author":"Y Eralp","year":"1999","unstructured":"Eralp Y, Davutoglu C, Uzunismail H, Oktay E. Efficacy of combination therapy with omeprazole, amoxicillin and clarithromycin treatment of patients with Helicobacter pylori associated gastritis and duodenal ulcer disease. Turk J Gastroenterol 1999;10:27\u201331","journal-title":"Turk J Gastroenterol"},{"issue":"Suppl 2","key":"9021_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/00365529609094541","volume":"31","author":"P Unge","year":"1996","unstructured":"Unge P. Review of H. pylori eradication regimens. Scand J Gastroenterol 1996;31(Suppl. 2):74\u201381","journal-title":"Scand J Gastroenterol"},{"key":"9021_CR36","first-page":"1528","volume":"3","author":"AF Cutler","year":"1997","unstructured":"Cutler AF, Vakil N. Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease. Am J Man Care 1997;3:1528\u201334","journal-title":"Am J Man Care"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-006-9021-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9021-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T19:15:39Z","timestamp":1587237339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-006-9021-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,26]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10,31]]}},"alternative-id":["9021"],"URL":"https:\/\/doi.org\/10.1007\/s11096-006-9021-y","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,26]]}}}